Ranbaxy and Nippon Chemiphar to dissolve Japanese joint venture
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo, and Nippon Chemiphar have agreed to dissolve their Japanese generics joint venture, Nihon Pharmaceutical Industry (NPI). Under the exit deal, Nippon Chemiphar is to purchase Ranbaxy's 50% shareholding in the venture, following which NPI will become a wholly-owned subsidiary of Nippon Chemiphar.